The Immunological and Molecular Evaluation of BARD1 Gene with the Breast Cancer Incidence and Prognosis among Iraqi Female Patients BARD1 Gene in Iraqi Breast Cancer
Abstract
Background: Breast cancer is a leading cause of cancer-related mortality worldwide. Genetic factors, including polymorphisms in DNA repair genes such as BARD1, may influence susceptibility. Inflammatory and tumor markers also play a role in cancer progression. This study aimed to investigate the association between BARD1 exon mutations, immunological and hormonal markers, and breast cancer risk in Iraqi women.
Methods: This case-control study included 100 patients with early onset breast cancer and 100 healthy controls, frequency matched for age and Body Mass Index (BMI). Serum levels of BARD1, MUC-1, CEA, CA15-3, estrogen, progesterone, prolactin, IL-1β, and TNF-α were measured using ELISA. Five BARD1 SNPs were genotyped using direct sequencing, and their association with breast cancer risk was assessed using logistic regression. The discriminative potential of the biomarkers was evaluated using Receiver Operating Characteristic (ROC) curve analysis.
Results: Significantly elevated levels of IL-1β, TNF-α, CEA, BARD1, and MUC-1 were observed in patients (p < 0.0001). ROC analysis showed discriminative potential for IL-1β (AUC = 0.88, 95% CI: 0.83–0.94), CEA (AUC = 0.78, 95% CI: 0.70–0.86), BARD1 (AUC = 0.77, 95% CI: 0.69–0.85), and MUC-1 (AUC = 0.73, 95% CI: 0.65–0.81). Three SNPs (rs2106145710, rs1695783243, and rs1574847014) were associated with increased breast cancer risk ( rs1574847014 OR = 11.67, 95% CI: 3.5–38.8), whereas rs10498023 showed a protective effect (OR = 0.33, 95% CI: 0.22–0.51).
Conclusion: Elevated levels of inflammatory and tumor markers, along with specific BARD1 polymorphisms, are associated with breast cancer risk in Iraqi women. These biomarkers may serve as noninvasive diagnostic tools, and genetic screening could aid in early risk stratification.
Full text article
References
Jabbar NM, Altaee MF, Naji RZ. Assessment of her2neu expression using immunohistochemistry in association with clinicopathological features and hormonal receptors in Iraqi breast cancer women patients. 2015;5(6) 1323-1330. http://ijps.aizeonpublishers.net/content/2015/6/ijps1323-1330.
Fishbein A, Hammock BD, Serhan CN, Panigrahy D. Carcinogenesis: Failure of resolution of inflammation? Pharmacology & therapeutics. 2021;218:107670. https://doi.org/10.1016/j.pharmthera.2020.107670
Zhao J, Xu L, Sun J, Song M, Wang L, Yuan S, et al. Global trends in incidence, death, burden and risk factors of early-onset cancer from 1990 to 2019. BMJ oncology. 2023;2(1):e000049. https://doi.org/10.1136/bmjonc-2023-000049
Neagu A-N, Bruno P, Johnson KR, Ballestas G, Darie CC. Biological basis of breast cancer-related disparities in precision oncology era. International Journal of Molecular Sciences. 2024;25(7):4113. https://doi.org/10.3390/ijms25074113
Ali CA, Lafta FM, Al Sayyid MM, Al-Rekabi A-ANG. BRCA1 gene expression is down regulated in both familial and sporadic breast cancer cases in Baghdad-Iraq. Iraqi Journal of Science. 2020:34-41. https://doi.org/10.24996/ijs.2020.61.1.4
Tarsounas M, Sung P. The antitumorigenic roles of BRCA1–BARD1 in DNA repair and replication. Nature Reviews Molecular Cell Biology. 2020;21(5):284-99. https://doi.org/10.1038/s41580-020-0218-z
Śniadecki M, Brzeziński M, Darecka K, Klasa-Mazurkiewicz D, Poniewierza P, Krzeszowiec M, et al. BARD1 and breast cancer: the possibility of creating screening tests and new preventive and therapeutic pathways for predisposed women. Genes. 2020;11(11):1251. https://doi.org/10.3390/genes11111251
Zhao S, Wang Q, Ni K, Zhang P, Liu Y, Xie J, et al. Combining single-cell sequencing and spatial transcriptome sequencing to identify exosome-related features of glioblastoma and constructing a prognostic model to identify BARD1 as a potential therapeutic target for GBM patients. Frontiers in Immunology. 2023;14:1263329. https://doi.org/10.3389/fimmu.2023.1263329
Fan Y, Chen X, Li H. Clinical value of serum biomarkers CA153, CEA, and white blood cells in predicting sentinel lymph node metastasis of breast cancer. International journal of clinical and experimental pathology. 2020;13(11):2889. https://pmc.ncbi.nlm.nih.gov/articles/PMC7716139/
Wu Q, Li M, Zhang S, Chen L, Gu X, Xu F. Clinical diagnostic utility of CA 15-3 for the diagnosis of malignant pleural effusion: A meta-analysis. Experimental and Therapeutic Medicine. 2015;9(1):232-8. https://doi.org/10.3892/etm.2014.2039
Hussain AM, Ali AH, Mohammed HL. Correlation between serum and tissue markers in breast cancer Iraqi patients. Baghdad Science Journal. 2022;19(3):3. https://doi.org/10.21123/bsj.2022.19.3.0501
Obeagu EI, Obeagu GU. Breast cancer: A review of risk factors and diagnosis. Medicine. 2024;103(3):e36905. https://doi.org/10.3892/etm.2014.2039
Ellingjord-Dale M, Vos L, Tretli S, Hofvind S, dos-Santos-Silva I, Ursin G. Parity, hormones and breast cancer subtypes-results from a large nested case-control study in a national screening program. Breast cancer research. 2017;19:1-21. https://doi.org/10.1186/s13058-016-0798-x
Schuler LA, O’Leary KA. Prolactin: the third hormone in breast cancer. Frontiers in endocrinology. 2022;13:910978. https://doi.org/10.3389/fendo.2022.910978
Altan-Bonnet G, Mukherjee R. Cytokine-mediated communication: a quantitative appraisal of immune complexity. Nature Reviews Immunology. 2019;19(4):205-17. https://doi.org/10.1038/s41577-019-0131-x
Boersma B, Jiskoot W, Lowe P, Bourquin C. The interleukin-1 cytokine family members: Role in cancer pathogenesis and potential therapeutic applications in cancer immunotherapy. Cytokine & growth factor reviews. 2021;62:1-14. https://doi.org/10.1016/j.cytogfr.2021.09.004
You D, Jeong Y, Yoon SY, A Kim S, Kim SW, Nam SJ, et al. Celastrol attenuates the inflammatory response by inhibiting IL‑1β expression in triple‑negative breast cancer cells. Oncol Rep. 2021;45(6):89. https://doi.org/10.3892/or.2021.8040
Cruceriu D, Baldasici O, Balacescu O, Berindan-Neagoe I. The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: molecular insights and therapeutic approaches. Cellular Oncology. 2020;43(1):1-18. https://doi.org/10.1007/s13402-019-00489-1
Koshy L, Anju A, Harikrishnan S, Kutty V, Jissa V, Kurikesu I, et al. Evaluating genomic DNA extraction methods from human whole blood using endpoint and real-time PCR assays. Molecular biology reports. 2017;44:97-108. https://doi.org/10.1007/s11033-016-4085-9
Wu J, Aini A, Ma B. Mutations in exon region of BRCA1‐related RING domain 1 gene and risk of breast cancer. Molecular Genetics & Genomic Medicine. 2022;10(3):e1847. https://doi.org/10.1002/mgg3.1847
Novelli F, Yoshikawa Y, Vitto VAM, Modesti L, Minaai M, Pastorino S, et al. Germline BARD1 variants predispose to mesothelioma by impairing DNA repair and calcium signaling. Proceedings of the National Academy of Sciences. 2024;121(29):e2405231121. https://doi.org/10.1073/pnas.2405231121
Toney NJ, Opdenaker LM, Frerichs L, Modarai SR, Ma A, Archinal H, et al. B cells enhance IL-1 beta driven invasiveness in triple negative breast cancer. Scientific Reports. 2025;15(1):2211. https://doi.org/10.1038/s41598-025-86064-1
Zhou J, Ottewell PD. The role of IL-1B in breast cancer bone metastasis. Journal of bone oncology. 2024;46:100608. https://doi.org/10.1016/j.jbo.2024.100608
Zhou J, Tulotta C, Ottewell PD. IL-1β in breast cancer bone metastasis. Expert Reviews in Molecular Medicine. 2022;24:e11. doi:10.1017/erm.2022.4
Malkova AM, Gubal AR, Petrova AL, Voronov E, Apte RN, Semenov KN, et al. Pathogenetic role and clinical significance of interleukin‐1β in cancer. Immunology. 2023;168(2):203-16. https://doi.org/10.1111/imm.13486
Qodir N, Pramudhito D, Hafy Z, Iman MB, Syafira F, Afladhanti PM, et al. Tumor Necrosis Factor-Alpha and Its Association With Breast Cancer: A Systematic Review. World Journal of Oncology. 2025;16(2):143. doi: 10.14740/wjon2532
Ma Y, Ren Y, Dai Z-J, Wu C-J, Ji Y-H, Xu J. IL-6, IL-8 and TNF-α levels correlate with disease stage in breast cancer patients. Advances in Clinical and Experimental Medicine. 2017;26(3):421-6. https://doi.org/10.17219/acem/62120
Krajcik RA, Massardo S, Orentreich N. No association between serum levels of tumor necrosis factor-α (TNF-α) or the soluble receptors sTNFR1 and sTNFR2 and breast cancer risk. Cancer Epidemiology Biomarkers & Prevention. 2003;12(9):945-6. https://aacrjournals.org/cebp/article/12/9/945/167878/No-Association-between-Serum-Levels-of-Tumor
Anoop TM, Soman S, Chacko S, Mathew M. Significance of serum carcinoembryonic antigen in metastatic breast cancer patients: A prospective study. World Journal of Clinical Oncology. 2022;13(6):529. DOI: 10.5306/wjco.v13.i6.529
Uygur MM, Gümüş M. The utility of serum tumor markers CEA and CA 15–3 for breast cancer prognosis and their association with clinicopathological parameters. Cancer Treatment and Research Communications. 2021;28:100402. DOI: 10.1016/j.ctarc.2021.100402
Grewal US, Kurzrock R. Mucin-1: a promising pan-cancer therapeutic target. npj Precision Oncology. 2025;9(1):218. DOI: 10.1038/s41698-025-01016-2
Jing X, Liang H, Hao C, Yang X, Cui X. Overexpression of MUC1 predicts poor prognosis in patients with breast cancer. Oncology reports. 2019;41(2):801-10. DOI: 10.3892/or.2018.6887
Maeda T, Hiraki M, Jin C, Rajabi H, Tagde A, Alam M, et al. MUC1-C induces PD-L1 and immune evasion in triple-negative breast cancer. Cancer research. 2018;78(1):205-15. DOI: 10.1158/0008-5472.CAN-17-1636
Atta Manu E, Bedu-Addo K, Titiloye N, Ameh-Mensah C, Opoku F, Duduyemi B. Expression of Tumour‐Associated MUC1 Is a Poor Prognostic Marker in Breast Cancer in Kumasi, Ghana. Journal of Oncology. 2020;2020(1):9752952. DOI: 10.1155/2020/9752952
ABDULHUSSEIN HA, ALWASITI EA, KHIRO NK. The role of VEGF levels in the differentiation between malignant and benign breast tumor. 2023. https://doi.org/10.12991/jrespharm.1686003
Zaleski M, Kobilay M, Schroeder L, Debald M, Semaan A, Hettwer K, et al. Improved sensitivity for detection of breast cancer by combination of miR-34a and tumor markers CA 15-3 or CEA. Oncotarget. 2018;9(32):22523. DOI: 10.18632/oncotarget.25077
Kwong A, Ho CY, Au CH, Ma ES. Germline BARD1 Mutation in High-Risk Chinese Breast and Ovarian Cancer Patients. Cancers. 2025;17(15):2524. DOI: 10.3390/cancers17152524
Chen Y-Z, Zuo D, Ren H-L, Fan S-J, Ying G. Bioinformatics analysis of expression and alterations of BARD1 in breast cancer. Technology in cancer research & treatment. 2019;18:1533033819892260. DOI: 10.1177/1533033819892260
Liu X, Zhang X, Chen Y, Yang X, Xing Y, Ma L. Association of three common BARD1 variants with cancer susceptibility: a system review and meta-analysis. International Journal of Clinical and Experimental Medicine. 2015;8(1):311. https://pmc.ncbi.nlm.nih.gov/articles/PMC4358457/
Suszynska M, Kozlowski P. Summary of BARD1 mutations and precise estimation of breast and ovarian cancer risks associated with the mutations. Genes. 2020;11(7):798. DOI: 10.3390/genes11070798
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394-424. DOI: 10.3322/caac.21492
Cybulski C, Kluźniak W, Huzarski T, Wokołorczyk D, Kashyap A, Rusak B, et al. The spectrum of mutations predisposing to familial breast cancer in Poland. International journal of cancer. 2019;145(12):3311-20. DOI: 10.1002/ijc.32492
Shimelis H, LaDuca H, Hu C, Hart SN, Na J, Thomas A, et al. Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing. JNCI: Journal of the National Cancer Institute. 2018;110(8):855-62. DOI: 10.1093/jnci/djy106
Alenezi WM, Fierheller CT, Recio N, Tonin PN. Literature review of BARD1 as a cancer predisposing gene with a focus on breast and ovarian cancers. Genes. 2020;11(8):856. DOI: 10.3390/genes11080856
Dorling L, Carvalho S, Allen J, González-Neira A, Luccarini C, Wahlström C, et al. Breast cancer risk genes—association analysis in more than 113,000 women. New England Journal of Medicine. 2021;384(5):428-39. DOI: 10.1056/NEJMoa1913948
Spurdle AB, Marquart L, McGuffog L, Healey S, Sinilnikova O, Wan F, et al. Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers. Cancer epidemiology, biomarkers & prevention. 2011;20(5):1032-8. doi: 10.1158/1055-9965.EPI-10-0909.
Kurdi M, Toonsi F, Alkhotani A, Maghrabi Y, Okal F, Enani M, et al. Pilocytic astrocytoma with BARD1 mutation: oncogenic pathways via DNA damage repair mechanism and MAPK/BRAF. Pathology. 2025;57(5):680-3. DOI: 10.1016/j.pathol.2025.02.005
Authors
Copyright (c) 2025 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.